Giorgio Caturegli, MD, BS
Hospital ResidentAbout
Research
Publications
2025
Real-world perioperative outcomes of neoadjuvant chemoimmunotherapy in non–small cell lung cancer
Caturegli G, Kaminski M, Canavan M, Ayoade O, Resio B, Boffa D. Real-world perioperative outcomes of neoadjuvant chemoimmunotherapy in non–small cell lung cancer. JTCVS Open 2025, 28: 554-564. DOI: 10.1016/j.xjon.2025.09.016.Peer-Reviewed Original ResearchNon-small cell lung cancerPathological complete responseNational Cancer DatabaseNeoadjuvant chemoimmunotherapyCell lung cancerChemoimmunotherapy patientsNeoadjuvant chemoradiotherapyPerioperative outcomesStage I to III non-small cell lung cancerIII non-small cell lung cancerLung cancerTreated with neoadjuvant chemoimmunotherapyNon-small cell lung cancer recurrenceOutcome of immunotherapyPeri-operative outcomesMethods Adult patientsInduction chemoimmunotherapyComplete responseNeoadjuvant chemotherapyNodal downstagingPerioperative therapyCancer DatabasePneumonectomy rateChemoimmunotherapyAdult patientsErratum to ‘Recent Survival Gains in Stage IV NSCLC by Sociodemographic Strata’ [JTO Clinical and Research Reports Volume 6 Issue 4 (2025) 100798]
Ayoade O, Canavan M, Zolfaghari E, Caturegli G, Kim S, Boffa D. Erratum to ‘Recent Survival Gains in Stage IV NSCLC by Sociodemographic Strata’ [JTO Clinical and Research Reports Volume 6 Issue 4 (2025) 100798]. JTO Clinical And Research Reports 2025, 6: 100850. DOI: 10.1016/j.jtocrr.2025.100850.Peer-Reviewed Original ResearchP1.07.31 Adjuvant Immunotherapy for Clinically Node-Negative Non-Small Cell Lung Cancer
Caturegli G, Canavan M, Ayoade O, Resio B, Boffa D. P1.07.31 Adjuvant Immunotherapy for Clinically Node-Negative Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2025, 20: s148-s149. DOI: 10.1016/j.jtho.2025.09.274.Peer-Reviewed Original ResearchP2.08.07 Lymph Node Yield and Survival Among Lung Cancer Patients Treated With Neoadjuvant Systemic Therapy
Caturegli G, Canavan M, Ayoade O, Resio B, Boffa D. P2.08.07 Lymph Node Yield and Survival Among Lung Cancer Patients Treated With Neoadjuvant Systemic Therapy. Journal Of Thoracic Oncology 2025, 20: s343. DOI: 10.1016/j.jtho.2025.09.643.Peer-Reviewed Original ResearchMortality Risk and Cause of Death Associated with Removal of the Adult Thymus: Analysis of the US Thymoma Population
Resio B, Canavan M, Caturegli G, Detterbeck F, Boffa D. Mortality Risk and Cause of Death Associated with Removal of the Adult Thymus: Analysis of the US Thymoma Population. Journal Of Thoracic Oncology 2025 PMID: 40865907, DOI: 10.1016/j.jtho.2025.08.017.Peer-Reviewed Original ResearchSurveillance Epidemiology and End ResultsNational Cancer DatabaseDuctal carcinoma in situPropensity-matched patientsThyroid cancerAdult thymusU.S. populationImmunologic end pointsCarcinoma in situFive-year survivalCancer incidencePartial thymectomyThyroid lobectomyResected breastLonger-term outcomesPartial mastectomyThyroid neoplasmsTotal thymectomyCancer DatabaseCause of deathNo significant differenceSecondary cancersSmall thymomaThymectomyEnd ResultsDefinitive radiation as a nonsurgical option after chemoimmunotherapy for stage III lung cancer.
Caturegli G, Canavan M, Ayoade O, Woodard G, Boffa D, Resio B. Definitive radiation as a nonsurgical option after chemoimmunotherapy for stage III lung cancer. Journal Of Clinical Oncology 2025, 43: 8072-8072. DOI: 10.1200/jco.2025.43.16_suppl.8072.Peer-Reviewed Original ResearchStage III non-small cell lung cancerIII non-small cell lung cancerNon-small cell lung cancerThree-year overall survivalNonsurgical optionsDefinitive radiationLocal therapyOverall survivalClinical stage III non-small cell lung cancerLung cancerClinical stage III patientsStage III NSCLC patientsStage III lung cancerSquamous cell carcinoma patientsStage III lung adenocarcinomaIII NSCLC patientsInitiation of radiationNon-operative formsCharlson-Deyo scoreIII lung cancerNational Cancer DatabaseStage III patientsTreated with radiationCell carcinoma patientsKaplan-Meier methodSurvival of patients diagnosed with stage IV cancer in 2020 based on COVID-19 status.
Ayoade O, Canavan M, Caturegli G, Zolfaghari E, Resio B, Woodard G, Boffa D. Survival of patients diagnosed with stage IV cancer in 2020 based on COVID-19 status. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e24041.Peer-Reviewed Original ResearchCancer patient survivalPatient survivalTumor behaviorCOVID-19 infectionCancer typesCharlson-Deyo scoreNational Cancer DatabaseSurvival of patientsKaplan Meier analysisCox proportional hazards modelsStage IV cancerAssociated with lower mortality riskProportional hazards modelCOVID-positive patientsMeier analysisCancer DatabaseLower mortality riskPositive patientsTreatment modalitiesDeyo scoreIV cancerImmune modulationImmunological consequencesCancer patientsYear mortalitySmoking Status of the US Cancer Population and a New Perspective From the National Cancer Database
Caturegli G, Zhu X, Palis B, Mullett T, Resio B, Boffa D. Smoking Status of the US Cancer Population and a New Perspective From the National Cancer Database. JAMA Oncology 2025, 11: 564-566. PMID: 40146125, PMCID: PMC11950973, DOI: 10.1001/jamaoncol.2025.0247.Peer-Reviewed Original ResearchRecent Survival Gains in Stage IV NSCLC by Sociodemographic Strata
Ayoade O, Canavan M, Zolfaghari E, Caturegli G, Kim S, Boffa D. Recent Survival Gains in Stage IV NSCLC by Sociodemographic Strata. JTO Clinical And Research Reports 2025, 6: 100798. PMID: 40212792, PMCID: PMC11985032, DOI: 10.1016/j.jtocrr.2025.100798.Peer-Reviewed Original ResearchNon-small cell lung cancerStage IV non-small cell lung cancerIV non-small cell lung cancerStage IV NSCLC patientsIV NSCLC patientsCell lung cancerMedian survivalNSCLC patientsLung cancerNon-small cell lung cancer patientsNational Cancer DatabaseKaplan Meier methodTwo-year survivalStratified Cox analysisAdjusted mortality riskMeier methodCancer DatabaseCox analysisEra 1NSCLC treatmentSurvival gainChemotherapy administrationNon-Hispanic blacksPatientsHispanic patients
2024
Brief Report: Should a prior cancer history be reevaluated as an exclusion for clinical trial participation?
Ayoade O, Canavan M, Caturegli G, Boffa D. Brief Report: Should a prior cancer history be reevaluated as an exclusion for clinical trial participation? Lung Cancer 2024, 198: 108032. PMID: 39561624, DOI: 10.1016/j.lungcan.2024.108032.Peer-Reviewed Original ResearchNon-small cell lung cancerAssociated with superior survivalSuperior survivalStage III NSCLC patientsCancer historyIII NSCLC patientsReceipt of immunotherapyNational Cancer DatabaseRegimens of chemotherapyStage IV patientsAnalyze overall survivalCell lung cancerKaplan Meier analysisStage III andCox proportional hazards modelsProportional hazards modelInnovative treatment approachesInfluence patient outcomesNSCLC patientsIV patientsOverall survivalImmunotherapy trialsCancer DatabaseMeier analysisNon-small